vTv Therapeutics Hits $67 Target After TD Cowen’s Bullish “Buy” Rating
TD Cowen gives vTv Therapeutics a bullish “Buy” rating with a $67 target—up 69%—highlighting its strong pipeline and potential upside for investors in biotech.
3 minutes to read
VTv Therapeutics Inc
vTv Therapeutics Inc: Navigating Financial Challenges and Uncertain Future in Biotech Sector
vTv Therapeutics Inc. faces significant financial and operational challenges, raising questions about its future viability and market position, despite its ambitious mission to revolutionize patient care through novel therapeutic agents.
3 minutes to read
vTv Therapeutics Shortens Type 1 Diabetes Trial, Aims for Faster Results with Protocol Amendment
vTv Therapeutics Inc. has accelerated its Type 1 Diabetes trial, CATT1, with a protocol amendment, aiming to bring a new treatment option to market more swiftly.
2 minutes to read